|
WO2021077101A1
|
|
Materials and methods for the treatment of disorders associated mutations in the irf2bpl gene
|
|
WO2021077115A1
|
|
Gene therapy targeting cochlear cells
|
|
WO2021050673A1
|
|
Assay for immune cell recovery
|
|
WO2021042048A1
|
|
Copper-atsm for treating neurodegenerative disorders associated with mitochondrial dysfunction
|
|
WO2021035120A1
|
|
Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
|
|
WO2021026075A1
|
|
Exon 44-targeted nucleic acids and recombinant adeno-associated virus comprising said nucleic acids for treatment of dystrophin-based myopathies
|
|
WO2021007260A2
|
|
Antibody compositions for disrupting biofilms
|
|
WO2020247536A1
|
|
Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies
|
|
WO2020236352A1
|
|
Optimized gene therapy targeting retinal cells
|
|
WO2020198675A1
|
|
Generation of chimeric antigen receptor (car)-primary nk cells for cancer immunotherapy using a combination of cas9/rnp and aav viruses
|
|
WO2020190682A1
|
|
Compositions and methods for diagnosing acute infectious peritonitis
|
|
WO2020186238A1
|
|
Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics
|
|
WO2020185698A1
|
|
Stat3 transcriptome for designing more potent nk cells
|
|
WO2020176614A1
|
|
Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
|
|
TW202033768A
|
|
Adeno-associated virus delivery of cln6 polynucleotide
|
|
WO2020163300A1
|
|
Adeno-associated virus delivery of cln3 polynucleotide
|
|
WO2020154207A1
|
|
A novel method for monitoring and treating oral cancer
|
|
WO2020154210A1
|
|
Methods for detecting and treating hepatic cancers
|
|
WO2020146544A1
|
|
A novel method for monitoring endometriosis and associated disorders
|
|
WO2020142479A1
|
|
Dux4 rna silencing using rna targeting crispr-cas13b
|
